Hola,
He estado buscando más información y según dicen hay rumores en Italia sobre la salida del producto. La fecha sería en diciembre de este año, epro claro, son solo rumores aunque deseo que sean ciertos porque menudas navidades más felices jejeje.
Aquí os dejo un enalce sobre la patente y aunque es bastante extensa y no me la he leido entera, me parece que viene la composición y explicación de los componentes de la loción y lo que hacen o producen en nuestro organismo:
https://www.google.com/patents/WO201517 ... l=en&hl=es
Voy a dejaros los últimos párrafos:
From the observations reported here, first of all, it can be inferred that the formulations object of the present invention are clinically efficient in:
· stopping hair loss; • promoting hair regrowth in areas with alopecia;
• strengthening and fortifying hair, bringing it back to its original state
both in male and female subjects with forms of hair reduction or actual alopecia due to different causes, and in menopausal women.
Formulations set up here additionally:
• do not contain potentially toxic substances or that may interfere with other active ingredients;
· are not irritating for the skin: even after long term application no evidence of irritation or inflammation was reported;
• are stable in time: analysis carried out on the content of the vials 30 days after preparation detects
· significant Ρζ values in terms of stability, particularly for formulations containing 2% or, better, 3% stearylamine
• an unchanged content of active substances enclosed in liposomes;
· can be stored at room temperature and in a ready-to- use form;
and, surprisingly
• act more quickly and more effectively: comparison tests clearly demonstrate that group 1 has a more rapid, more substantial improvement and, mainly, it involves all the patients as compared with group 2, treated with Lotion B.
Again, it should be recalled that Lotion B contains PGE1 and equol in 1:1 ratio, while Lotion A contains 30% less of active substance (DGLA) . This means that the findings of the present invention exert an unexpectedly superior effect than what known, at markedly lower concentrations of active substances.
These results should be attributed only to the formulation set up herein. In fact, it is clear from data analysis that patients treated with PGE1 alone, even at the concentrations described in WO2011/095938, experience a very modest variation of the situation. Still different and most important is the observation of group 5, treated with DGLA alone at the same concentration employed in Lotion A: there is no reduction in hair loss and even less any regrowth, not even of fuzz.
The extraordinary effects that are displayed by the compositions of the present invention are then due to synergies between single components, promoted by the characteristics of the liposome suspensions used.
Pd. Os dejo la web, email y la cuenta de Twitter de la empresa Fidia:
http://www.fidiapharma.com/en/
E-mail:
info@fidiapharma.it
https://twitter.com/Fidiapharma
Un saludo
